Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is projected to release its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $47.0330 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Performance

Shares of NASDAQ:PHAT opened at $13.46 on Thursday. The firm has a 50 day simple moving average of $11.91 and a 200 day simple moving average of $8.49. Phathom Pharmaceuticals has a 52 week low of $2.21 and a 52 week high of $19.50. The company has a market cap of $954.85 million, a PE ratio of -2.85 and a beta of 0.43.

Institutional Investors Weigh In On Phathom Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in shares of Phathom Pharmaceuticals by 13.4% during the 2nd quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock valued at $39,703,000 after buying an additional 489,260 shares during the last quarter. Moore Capital Management LP bought a new position in Phathom Pharmaceuticals during the second quarter valued at approximately $5,754,000. Ameriprise Financial Inc. bought a new position in Phathom Pharmaceuticals during the second quarter valued at approximately $1,734,000. JPMorgan Chase & Co. lifted its stake in Phathom Pharmaceuticals by 0.8% in the second quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock valued at $1,328,000 after acquiring an additional 1,123 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Phathom Pharmaceuticals by 508.2% during the 1st quarter. AQR Capital Management LLC now owns 107,399 shares of the company’s stock worth $673,000 after purchasing an additional 89,741 shares during the last quarter. 99.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PHAT has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen raised Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.